Li Jing, Zhang Jing, Hao Qingfei, Du Yanna, Lu Jie, Chen Haoming, Cheng Xiuyong
Department of Neonatology, The First Affiliated Hospital of Zheng Zhou University, Zhengzhou, China.
Front Pediatr. 2022 Apr 11;10:836220. doi: 10.3389/fped.2022.836220. eCollection 2022.
To determine the association between the time interval from antenatal corticosteroids administration to delivery and neonatal complications in diabetic mothers undergoing early term (37+0 to 38+6 weeks) scheduled cesarean section (ETSCS).
A retrospective cohort study of women with any form of diabetes in pregnancy undergoing ETSCS was included. Cases were stratified into the following groups based on the time interval from the first dose of corticosteroids administration to delivery: <2, 2-7, and >7 days. Women undergoing ETSCS, who did not receive corticosteroids were included as controls. We assessed the association between the time interval and neonatal outcomes in a multivariate regression model that controlled for potential confounders. Primary outcomes were the incidence of respiratory distress syndrome (RDS)/transient tachypnea of the newborn (TTN) and neonatal hypoglycemia.
The study cohort comprised 1,165 neonates. Of those, 159 (13.6%) were delivered within 2 days of maternal corticosteroids administration, 131 (11.2%) were delivered within 2-7 days after maternal corticosteroids administration, and 137 (11.8%) delivered more than 7 days after maternal corticosteroids administration. The remaining 738 (63.3%) were not exposed to corticosteroids. Multivariate analysis demonstrated that delivery within any time of antenatal corticosteroids administration was not associated with decreased risks of RDS/TTN. The risk of neonatal hypoglycemia was highest in the delivery of <2 days group (adjusted odds ratio [aOR]: 2.684, 95% confidence interval [CI]: 1.647-4.374 for control group; aOR: 2.827, 95% CI: 1.250-6.392 for delivery 2-7 days group; aOR:2.975, 95% CI: 1.265-6.996 for delivery >7 days group).
Corticosteroids treatment for diabetic mothers undergoing ETSCS was not associated with beneficial neonatal respiratory outcomes. In addition, delivery, <2 days after antenatal corticosteroids administration was associated with an increased risk of neonatal hypoglycemia.
确定在接受早期足月(37⁺⁰至38⁺⁶周)计划性剖宫产(ETSCS)的糖尿病母亲中,从产前使用糖皮质激素至分娩的时间间隔与新生儿并发症之间的关联。
纳入了对任何形式妊娠糖尿病且接受ETSCS的女性进行的一项回顾性队列研究。根据从首次使用糖皮质激素至分娩的时间间隔,将病例分为以下几组:<2天、2 - 7天和>7天。未接受糖皮质激素的接受ETSCS的女性作为对照组。我们在一个控制了潜在混杂因素的多变量回归模型中评估了时间间隔与新生儿结局之间的关联。主要结局是呼吸窘迫综合征(RDS)/新生儿短暂性呼吸急促(TTN)的发生率以及新生儿低血糖。
研究队列包括1165例新生儿。其中,159例(13.6%)在母亲使用糖皮质激素后2天内分娩,131例(11.2%)在母亲使用糖皮质激素后2 - 7天内分娩,137例(11.8%)在母亲使用糖皮质激素后7天以上分娩。其余738例(63.3%)未接触糖皮质激素。多变量分析表明,在产前任何时间使用糖皮质激素后分娩与RDS/TTN风险降低无关。新生儿低血糖风险在<2天组分娩时最高(对照组调整优势比[aOR]:2.684,95%置信区间[CI]:1.647 - 4.374;2 - 7天组分娩时aOR:2.827,95% CI:1.250 - 6.392;>7天组分娩时aOR:2.975,95% CI:1.265 - 6.996)。
对接受ETSCS的糖尿病母亲进行糖皮质激素治疗与有益的新生儿呼吸结局无关。此外,产前使用糖皮质激素后<2天分娩与新生儿低血糖风险增加有关。